Puma Biotechnology: Funding, Investors & Team (Sep 2026)
Puma Biotechnology, Inc., is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB-272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer.
Puma Biotechnology has raised $10.0M across 1 funding round on record, the most recent a Post-IPO Equity of $10.0M announced in Mar 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Puma Biotechnology Company Profile and Key Stats
Latest funding round on record: Mar 2022.
Puma Biotechnology Funding Rounds
Puma Biotechnology Founders and Leadership Team
Contact details for the Puma Biotechnology team: 1 of 1 has an email address on file.
Start 14-day free trial →Puma Biotechnology Funding Compared to Other Biotechnology Startups
Puma Biotechnology's latest round of $10.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Puma Biotechnology in Biotechnology and Los Angeles
Companies Similar to Puma Biotechnology
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Puma Biotechnology Funding FAQs
What does Puma Biotechnology do?
Puma Biotechnology, Inc., is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB-272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer.
How much funding has Puma Biotechnology raised?
Puma Biotechnology has raised $10.0M across 1 round on record. The most recent is a Post-IPO Equity of $10.0M announced in Mar 2022.
When did Puma Biotechnology last raise funding?
Puma Biotechnology's most recent funding round on record is a Post-IPO Equity of $10.0M, announced in Mar 2022.
Who is the CEO of Puma Biotechnology?
Alan Auerbach is listed as CEO at Puma Biotechnology.
Where is Puma Biotechnology headquartered?
Puma Biotechnology is based in Los Angeles, California, United States.
How many employees does Puma Biotechnology have?
Puma Biotechnology is in the 251-500 employee band.
How does Puma Biotechnology's funding compare to other Biotechnology startups?
Puma Biotechnology's latest round of $10.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Puma Biotechnology Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Puma Biotechnology is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.